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Objective: To improve the identification of patients at risk of developing cytomegalovirus (CMV) disease. 
Materials and methods: In a prospective study of 50 kidney or liver transplant patients who developed fever, 133 
EDTA blood samples were analyzed, using two tests to measure CMV DNA: a 10-fold limiting dilution of an extract of 
2 million leukocytes for CMV PCR, and a CMV hybrid capture assay. Both tests were compared with virus isolation, using 
an equivalent amount of leukocytes as a base for all three tests. 
Results: The limiting-dilution CMV PCR and the hybrid capture assay presented relatively similar changes of sensitivity 
and specificity at different CMV DNA concentrations. The kinetics of the positive and negative predictive values were 
also comparable. A higher CMV DNA load corresponded to an increased risk of developing CMV disease. Furthermore, 
an increase in the endpoint dilution of a positive CMV PCR also corresponded to more severe disease. After antiviral 
treatment, the CMV PCR decreased by at least 100-fold (2 loglo) in 10 cases and by 10-fold (1 loglo) in  five cases. Thus, 
there was a decrease in 15 of 18 (83%) patients. Similarly, with the hybrid capture assay, the amount of CMV DNA 
decreased about 100-fold in five patients and decreased by about 0.5 genome equivalents in  five cases, i.e. in 10 of 12 
(83%) patients. 
Conclusion: Both methods proved clinically useful for detecting patients at risk of developing CMV disease and for 
monitoring antiviral treatment in solid organ transplant patients. 
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INTRODUCTION 
Cytomegalovirus (CMV) infection and disease coil- 
tinue to be significant complications of immuno- 
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suppressive treatment in recipients of organ transplants. 
Early antiviral therapy may reduce the degree of 
immunosuppression and leucopenia caused by CMV 
[l,?]. I t  may also reduce the risk of CMV-induced 
allograft rejection and development of chronic graft 
dysfunction 13-61. The rapid and sensitive detection of 
CMV DNA in peripheral blood, using the polymerase 
chain reaction (PCR), may make it possible to treat 
CMV infection early [7-131. A close relation between 
an increase in CMV DNA load in blood and the 
development of symptomatic CMV disease has been 
suggested [13-211. Quantification of the CMV load 
should provide more information about the state and 
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severity of infection in immunocompromised patients. 
Uncontrolled antiviral treatment could then be avoided. 
Three laboratories compared CMV PCK per- 
formed on leukocytes from bone marrow transplant 
patients and found that the total amount of human 
DNA used iii the assays was of critical importance for 
coniparison of results [Z]. The clinical relevance of 
these findings for solid organ transplant patients was 
addressed in the present study, using two concen- 
trations of leukocytes. We applied two techniques, a 
limiting-dilution nested CMV PCR on leukocyte 
extracts, and a quantitative hybrid capture CMV 
RNA:DNA assay to compare the CMV DNA load 
related to symptoniatic disease and to monitor anti- 
viral treatment in kidney and liver transplant patients. 
The efficacies of these two tests were compared to 
each other and to virus isolation, using an equivalent 
amount of leukocytes as a base for all three tests. Our  
virus isolation from blood mononuclear cells has 
previously been shown to correlate with symptomatic 
CMV disease in organ transplant patients [23]. 
MATERIALS AND METHODS 
Patients and samples 
There were 28 kidney and 23 liver transplant patients. 
The niean age ofthe 17 females was 49.6 years and that 
of the 33 males was 46.2 years. Immunosuppression 
consisted of cyclosporin A (CyA; Sandoz Ltd, Basel, 
Switzerland) and prednisolone in renal transplant 
patients, and of a combination of these drugs with 
azathioprine in liver transplant patients [24,25]. 
Tacrolimus (Prograf; Fujisawa, Munich, Germany) was 
used instead of CyA in seven patients. CMV infection 
and disease were diagnosed in 13% (7/50) and 16% 
(8/50) of the patients, respectively. In the remaining 35 
patients, no signs or symptoms of CMV-associated 
infection were detected. The mortality was 6% (3150) 
in the patients: two patients died with CMV hepatitis 
and one patient with hepatitis and pneumonitis. 
One hundred and thirty-three leukocyte samples 
of EDTA blood were obtained from these 50 organ 
transplant recipients between March and September 
1993. Informed consent was received from all of them. 
The saniples were collected prospectively at the onset 
of febrile episodes, with repeated weekly sampling until 
no CMV DNA was detected within the first 3 months 
after transplantation. Patients without fever were not 
included, and neither were results obtained 3 months 
after transplantation. In 38% (19/50) of the patients, 
more than two samples were examined (90 samples). In 
the others, one sample in 19 patients and two samples 
in 12 patients were obtained. 
Definitions of CMV status of the patients 
Severe CMV disease was defined as pneumonia/ 
pneumonitis, gastrointestinal disease and hepatitis, in 
combination with positive CMV detection in the 
affected organ [23,36,37]. For the diagnosis of CMV 
pneumonia, the presence of CMV in bronchoalveolar 
lavage fluid or tissue material and interstitial pulmonary 
infiltrates or hypoxia were required [26, 281. For the 
diagnosis of enteritis/colitis and hepatitis, the presence 
of CMV had to be demonstrated in the gastrointestinal 
tract or a liver biopsy specimen [25,26,29]. The CMV 
syndrome, dso included in the category of CMV 
disease, was characterized by an otherwise unexpldined 
fever for 1 week with leucopenia and/or thrornbo- 
cytopenia, and possibly with headache, myalgia or 
arthralgia, in combination with positive CMV isolation 
from the peripheral blood [33,26]. 
Asymptomatic CMV infection was defined as 
virologic evidence of CMV viremia, without clinical 
symptoms of CMV disease. CMV viremia was defined 
as positive virus isolation from peripheral blood 1331. 
Virus isolation 
Virus isolation and sometimes a rapid variant, using 
short-term culture and immunofluorescence, were 
performed on each leukocyte sample of 2 million 
leukocytes [23]. When performed in a standardized 
way with equivalent amounts of leukocytes per assay 
and an incubation time of 72 h for the short-term 
culture, the isolation and the rapid culture methods 
have been shown to give indistinguishable results 1331. 
In addition, biopsy specimens of the liver, gastro- 
intestinal tract and lungs, as well as samples of the 
bronchoalveolar lavage fluid from 35 patients, were 
examined for the presence of CMV, using imniuno- 
histopathologic methods, indirect immunofluorescence 
with nionoclonal antibodies against CMV, and P C R  
[25,28,29]. 
limiting-dilution nested PCR of CMV DNA 
Leukocytes for CMV PCK were separated from 5 niL 
ofEDTA blood [23,30,31]. Nested CMV PCR was per- 
formed after DNA extraction from 2 million leukocytes 
into 50 pL of lysis buffer [23,33]. As a coniparison. 
5C)O 000 leukocytes were also collected. One-tenth of 
the volume (5 11) was subjected to DNA aniplification 
as a nested P C R  with two sets of primers in two steps 
in single tubes for all samples [23,32]. The amplified 
product was separated in an agarose gel, with ethidium 
bromide to allow detection under ultraviolet light. 
A 10-fold limiting dilution in distilled water of the 
leukocyte extracts of PCR-positive samples was per- 
formed. Each sample was first diluted 1 &fold in three 
steps and, ifnecessary in three more 10-fold steps, until 
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the CMV P C R  became negative in two successive 
dilution steps. 
Quantitative CMV DNA detection, using the hybrid capture 
assay 
The amount of CMV DNA was also analyzed, using a 
hybrid capture assay in solution (Laboratories Murex, 
Chatillon, France) [33]. After discussion with the 
manufacturer, we used extracts from 2 million leuko- 
cytes instead of the original 3.5 mL of blood recom- 
mended in the manufacturer’s protocol. This permitted 
more direct comparison of the sensitivity and speci- 
ficity of the two techniques. Briefly, DNA obtained 
from 2 million leukocytes was denatured by base 
hydrolysis and hybridized to unlabeled R N A  probes. 
Sometimes the extract from 500 000 leukocytes was 
used. In this case the value was multiplied by four to 
make it comparable with the other results. 
This assay uses a specific probe against the CMV 
major IE genome, complementary to approximately 
40 000 bp of the CMV genome. The resulting RNA:  
DNA hybrids are captured onto the surface of a tube 
coated with anti-RNA:DNA hybrid antibodies. Bound 
hybrids are detected with an alkaline phosphatase- 
conjugated antibody, also specific for RNA:DNA 
hybrids, and quantified with chemiluminescence as 
relative light units. The luminometer measures the 
emitted signal, which is proportional to the amount of 
DNA in the sample and is compared with a calibration 
curve. 
Statistical methods 
Fisher’s exact two-tailed test was used 
RESULTS 
Experimental conditions for the limiting-dilution PCR and 
the hybrid capture assay 
The experimental sensitivity of PCR,  using the CMV 
genome of 230 kbp (from the Swedish Institute for 
Infectious Disease Control, Stockholm, Sweden), 
which was diluted in DNA extracted from 2 million 
leukocytes from a healthy CMV-seronegative donor, 
reached a detection limit of 1-5X10-l5 g CMV DNA 
in the amount analyzed, corresponding to 4-20 CMV 
genome equivalents. According to the manufacturer, 
the detection limit of the hybrid capture assay is 5 ~ 1 0 ~  
CMV genome equivalents in 3.5 mL blood, which 
corresponds to 17 500 genomes per assay. 
The Poisson distribution may affect the endpoint 
of CMV DNA in a limiting-dilution series. The choice 
of two consecutive negative values, following the last 
positive one in a series, would reduce the influence of 
this factor on our results. A negative result between two 
positive results in a dilution series occurred at a 
frequency of 3.7%. The risk of still another positive 
P C R  after two negative results would be much less and 
was regarded as negligible. 
Comparison of qualitative and quantitative PCR in patients 
at risk of developing CMV disease 
The qualitative nPCR (nested PCR) was positive in 
49% (65/133) of the samples of 2 million leukocytes 
and in 42% (56 of 133) of the samples of 500 000 
leukocytes. All patients with CMV disease (eight cases) 
and those with asymptomatic CMV infection (seven 
cases) were CMV P C R  positive in their first sample. 
Among these patients, six of eight and six of seven, 
respectively, were also positive in the PCR, based on 
500 000 leukocytes. The positive predictive value of 
the qualitative P C R  increased from 0.24 (8/33) to 0.53 
(9/15) when based on two successive positive nPCR 
tests. In the 35 patients without a positive CMV 
isolation, 49% (17 cases) were P C R  negative as well, 
while the other 51% (1 8 cases) had only a single positive 
CMV P C R  sample. In all these 35 patients, another 
cause of the febrile episode was identified. These single 
PCR positive samples were PCR negative in the follow- 
ing 10-fold dilutions. Thus, screening the samples using 
undiluted nested CMV PCR was necessary to detect 
all CMV isolation-positive samples (Table 1). 
The limiting 10-fold dilution of CMV DNA- 
positive samples showed, even from a dilution of lo-’, 
both high sensitivity and specificity (Table 1). The 
positive predictive value for CMV disease was 0.5 at a 
dilution level of lo-’ and gradually increased to 1.0 at 
a dilution of lo-’ (Table 2). There was a significant 
association with CMV disease at a dilution of ?lo-’, 
both in samples (p<0.0001; Table 1) and in patients 
(p=0.0004; Table 2). In addxion, three of six patients 
(50%) with CMV P C R  positivity at dilutions 
finally died with severe CMV disease after liver trans- 
plantation. The negative predictive values were high at 
all drlutions. 
Qualitative comparisons of hybrid capture assay compared 
to virus isolation and PCR 
Fibroblast culture for isolating CMV was successful in 
71 of 74 blood samples, which were also examined 
using the hybrid capture assay and PCR. The hybrid 
capture assay detected CMV in 14 of 16 (88%) samples 
positive for virus isolation, while P C R  detected all 
16 samples. The hybrid capture assay also detected 
CMV in 30 of 55 (55%) isolation-negative samples. 
The sensitivity and specificity of the hybrid capture 
assay, compared with virus isolation, were 0.9 and 0.5, 
respectively, giving an agreement of 55%. 
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Table 1 Relation between C M V  DNA load in  leukocyte samples according to  the limiting-dilution C M V  PCR and CMV 
status at the time point of the obtained sample 
Positivc CMV isolation in patients with: 
CMV not 
detected by Asymptomatic CMV 
virus isolation CMV infection msease Total 
CMV PCR (4 (4 ( 4 (4 Sensitivity Specificity 
Negative 52 0 n 52 1 .o 0.0 
Undiluted positive 39 3 I 41 0.8 0.5 
10-1 7 1 1 9 0.8 11.8 
lo-' h 4 4 11 0.7 0.9 
10-3 3 1 4 8 u.3 0.9 
1u-' &. 0 1 4 0.1 1.0 
10-5 1 0 1 2 0.04 1 .n 
7 
7 7 
Total 110 9 14 133 
Table 2 Relation between CMV DNA load according to  the limiting-dilution C M V  PCli and CMV disease in  organ 
transplant patients 
Positive CMV isolation in patients with: 
CMV not 
detected by Asymptomatic CMV Po71 tive Negative 
virus isolation CMV infection disease Total predictivr predictive 
CMV PCK ( n) ( 4 (4 (4 values values 
Negative 16 0 0 l h  0.0 1 .o 
in- '  1 u 1 - (1.5 1 .o 
1 0 - 3  1 u 1 .. 0.0 0.9 
10-4 0 1 1 3 0.7 0.9 
1 0 - 5  u 0 1 .I) 0 . X  
Total 35 7 8 50 
Undiluted positive 16 3 0 19 0.0 1 0 
10-2 1 3 6 0.i 0.9 
9 
3 
> 
7 
7 7 
The results of the hybrid capture assay were 
compared to detection of CMV DNA, using PCK in 
7 1 samples. Among 57 samples that were positive with 
PCR, 36 (63%) were also positive with the hybrid 
capture assay, whereas eight of 13 (57%) samples that 
were negative with PCR were positive with the hybrid 
capture assay. 
Twentytwo of the 50 patients were available for 
assessing differences in the detection of CMV, using the 
hybrid capture assay, PCR and virus isolation. Among 
patients with CMV detectable by virus isolation (12 
patients with 16 samples), there was a similar frequency 
of patients with CMV-associated symptoms, seven of 
16 (six of 16 were unevaluable) with the hybrid capture 
assay and seven of 33 with PCK. 
Application of hybrid capture assay in patients with CMV 
disease 
The range of sensitivity of the hybrid capture assay in 
detecting CMV compared with virus isolation was 
from 0.9 to 0.4, while the specificity increased from 
0.5 to 1.0 (Table 3 ) .  
A positive hybrid capture assay was associated with 
the risk of developing CMV disease (y=0.006) (Table 
3). The highest load of CMV DNA obtained with the 
hybrid capture assay was 1.2 ~ 1 0 "  genome equivalents 
per assay among patients with CMV disease, as com- 
pared to 1.5 ~ 1 0 '  genome equivalents per assay among 
patients with asymptomatic CMV infection (Table 4). 
A level of 21.0Xl0' genome equivalents per assay in 
the hybrid capture assay tended to distinguish between 
patients with or without CMV disease when only the 
sample with the highest CMV DNA load per patient 
was considered, (p=0.074) (Table 3).  
The three patients with a fatal outcome from CMV 
disease were found to have a range of 3.0X10' to 
1 .2x106 genome equivalents per assay. However, seven 
of eight patients with a CMV DNA load of lo4 genome 
equivalents/?. million leukocytes level as well as seven 
of eight patients with a load of 10' genome equi- 
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Table 3 Relation between CMV DNA load in leukocyte samples using the hybrid capture system and CMV status at the 
time point of the obtained sample 
Positive CMV isolation in patients with: 
CMV not 
detected by Asymptomatic CMV 
CMV DNA virus isolation CMV infection disease Total 
load (pg/mL) ( 4 ( 4 (4 (4 Sensitivity Specificity 
Negative 26 2 1 29 0.9 0.5 
10' u 0 0 0 0.9 0.5 
11)' & 0 0 2 0.9 0.5 
104 15 4 6 15 0.4 0.9 
1 0 5  5 2 6 13 0.0 1 .n 
10" 1 0 0 1 0.0 1.u 
Total 53 8 14 74 
7 
1 0 3  3 0 1 4 0.8 0.6 
Table 4 Relation between CMV DNA load using the hybrid capture system and CMV disease in organ transplant patients 
Positive CMV isolation in patients with: 
CMV not 
detrcted by Asyinptomatic CMV Positive Negative 
CMV DNA virus isolation CMV infection disease Total predictive predictive 
load (pg/niL) 04 ( 4 (4 ( 4 values values 
Negative 4 1 I) 5 0.0 1.0 
3 0' ( 1  o 0 0 0.0 1 .o 
102 0 n 0 0 0.0 1 .0 
10' 0 0 0 0 0.0 1 .0 
104 3 3 '. 8 0.4 0.9 
10' I 1 4 8 0.6 0.7 
10'' 1 )  0 1 1 1 .o 0.7 
Total 9 6 7 22 
1 
7 7 
valents/2 million leukocytes, respectively, survived. 
The positive predictive value for detecting patients with 
CMV disease was present at levels 2 lo4 genome equi- 
valents per assay. The negative predictive values were 
high at all levels of CMV DNA (Table 4). 
Comparison of limiting-dilution PCR and the hybrid capture 
assay for CMV DNA quantification over time in individual 
patients with CMV disease 
The amount of CMV DNA detected using the 
limiting-dilution P C R  and the hybrid capture assay is 
shown in four representative patients with CMV disease 
in Figure 1. The results of the 19 patients with 2 3  
samples showed that the two techniques had similar 
kinetics in the changes of CMV DNA load (data not 
shown). 
Monitoring of the effect of antiviral treatment on CMV DNA 
load 
CMV was monitored during 23 courses of antiviral 
treatment with ganciclovir (Cymevene; F. Hoffman-La 
Roche AG, Basel, Switzerland) and/or foscarnet 
(Foscavir; Astra, Sodertalje, Sweden) in 22 patients, 18 
of whom were evaluable. One patient, although treated 
twice because of a recurrence of CMV hepatitis and 
pneumonitis, subsequently died. With the limiting- 
dilution PCR, the highest dilution level for amplifiable 
CMV DNA was lops  before the initiation of antiviral 
therapy (Figure 2a). After antiviral treatment the CMV 
P C R  decreased by at least two loglo values in 10 cases 
and one loglo in five cases, resulting in a negative P C R  
in four and three treatments, respectively. Thus, there 
was a measurable decrease in 15 of 18 (83%) patients. 
The amount of CMV DNA increased during treatment 
in one patient, who later died of CMV disease (Figure 
3a, patient 3) .  In the remaining two patients, the 
amount of CMV DNA remained unchanged (Figure 
2a, patients 16 and 17). 
Twelve of the 33 antiviral treatment courses could 
be evaluated using the hybrid capture assay (Figure 2b). 
Five treatments resulted in about a 100-fold reduction 
and CMV DNA became undetectable, and another five 
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Figure 1 Kinetics of the viral load using the limiting-dilution CMV PCR and the CMV hybrid capture syyteni in four 
liver-trxxplantcd patients with CMV disease. The amount of CMV DNA, using the 10-fold limiting dilution I ’CX (- - -, 
loglll curve) and the hybrid capture s y ~ t e m  (-), is presented in relation to the time after the onset offcver. Antiviral 
treatment, given to three patients, is marked above the curves. The relative amount of CMV DNA is indicated on the ))-axis, 
including a reference to the negative samples. 
treatments showed a decrease of about 0.5 genome 
equivalents. Thus, 10 of  13 (8356) treatments resulted 
in a reduction in the C M V  D N A  load. T h e  hybrid 
capture assay was  negative in one paticnt before, during 
m d  after the antiviral treatment, which had been started 
because of  a positive PCR (not presented in  Figure ?b). 
T h e  reiriaining patient showed an increasing C M V  
D N A  load, a finding also made when the 10-fold 
limiting-dilution PCR was used (Figure 3b, patient 3).  
T h e  two techniques were observed to have the 
came kinetics in changes during the antiviral courses in  
11 of 11 courses malyzed in  patients with C M V  disease 
or asymptomatic C M V  infection. 
DISCUSSION 
T h e  limiting-dilution nested PCK of C M V  D N A  and 
the hybrid capture assay were used to measure the 
relationship of C M V  DNA load to the risk of 
developing C M V  disease in  solid organ transplant 
patients. A gradual increase in  the aniount o f  C M V  
DNA, detected by both the limiting-dilution PCK and 
the hybrid capture assay, reflected an increase in the risk 
of  developing C M V  disease. In addition, positive results 
of  C M V  PCR at increasingly high dilution levels also 
corresponded to  the severity of the disease. Both ass~ys 
proved to be  useful for monitoring the C M V  DNA 
load during antiviral therapy. 
We wished to compare the two quantitative tests 
with an independent but standardized assay, virus 
isolation, using an equivalent amount of leukoc p s  as 
a base in all three assays, though it is difficult to compare 
the tests at the molecular and cellular level, as further 
processing was different. O u r  virus isolation and the 
short-term culture are both standardized with regard to 
the number of leukocytes used and have previoucly 
been shown to correlate with the presence of syniptorns 
and diseace [33,34,35]. O u r  qualitative nested single- 
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Figure 2 (a) The CMV DNA load, measured by the limiting-dilution PCR, in relation to the antiviral treatment in 18 
courses. The treatment consisted of either intravenous ganciclovir, 10 mg/kg per day for 7-14 days, followed by intravenous 
maintenance therapy of 5 mg/kg per day, 5 days per week, for 2-3 weeks, or intravenous foscarnet, 60 mg/kg per day, three 
times daily for 7-3 weeks. The dilution factor lo-' for CMV DNA P C R  is indicated on the y-axis. The overlapping lines 
have been adjusted slightly so that they can be distinguished. (b) The CMV DNA load, measured by the CMV hybrid 
capture system, in relation to antiviral treatment in 11 of 17 courses. The treatment consisted of ganciclovir or foscarnet. 
The amount of CMV genomes is given on the y-axis. The overlapping lines have been adjusted slightly so that they can be 
distinguished. 
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tube P C K  has a robust reproducibility and has proven 
useful in clinical practice [23]. It has been shown 
that the amount of patient material is of paramount 
importance for the sensitivity of CMV P C R  [22,36]. 
Therefore, in order to facilitate comparisons with other 
laboratories ["I, we included in this study a qualitative 
PCR,  based on 500 000 leukocytes, without detecting 
any significant advantage. 
The semiquantitative [37,38] limiting-dilution P C R  
was previously found to give an appropriate precision 
in bone marrow transplant patients and, in our pre- 
liminary report, in solid organ transplant patients 
[21,22]. It might be argued that the hybrid capture assay 
was not done strictly in accordance with the 
manufacturer's instructions 1331. However, when used 
with a constant volume of whole blood, this test does 
not compensate for differences in leukocyte counts in 
various blood saniples [22,39]. It is well known that 
CMV DNA is primarily located in polymorphonuclear 
cells during viral activation. In both bone marrow and 
solid organ transplant patients, CMV disease is often 
accompanied by leucopenia [40-32]. We wished to 
optimize the comparison by using a standardized 
leukocyte count; that is, the same starting material was 
used in all three tests. 
The hybrid capture assay and the limiting-dilution 
PCR were comparable when used to predict the risk 
of developing CMV disease, based on their negative 
and positive predictive values. Also, in recent studies 
using an improved hybrid capture assay in renal, 
pancreas/renal and liver transplant patients, a CMV 
DNA level for developing disease was identified 
[13,41]. However, the results of the hybrid capture assay 
in the present study did not identify patients with severe 
CMV disease from those with less severe CMV 
affection as well as the limiting-dilution PCR.  
If two successively positive CMV DNA results 
were used, which is often the case in pre-ernptive 
therapy based on qualitative PCK in leukocyte samples, 
the positive and negative predictive values of the hybrid 
capture assay for CMV disease did not improve, while 
the positive predictive value of P C R  doubled. Thus, 
the PCR-positive samples were now restricted to 
pdtients with positive virus isolation in their leukocytes. 
However, it would probably not be necessary to await 
a second positive result of the hybrid capture technique 
before starting antiviral treatment. 
Gerdes et a1 used competitive P C R  in 37 renal 
transplant patients [l3]. They found a correlation 
between an increasing amount of CMV DNA and the 
development of symptomatic CMV disease. Similar 
findings were made by Mutinier et a1 [ X I ,  in a study 
of 32 liver transplant patients, using single PCK with 
dii enzyme-linked imniunosorbent assay. In the latter 
study, however, overlapping peak viral loads were noted 
in patients with asymptomatic CMV infection and 
those with CMV disease. The optimum would be to 
define a CMV DNA load predicting symptomatic 
infection to allow institution of pre-emptive antiviral 
treatment. This might decrease the presumed late CMV 
complications, such as chronic graft dysfunction [3 ,3] .  
The present strategy of screening with a qualitative 
P C R  allowed detection of all CMV isolation-positive 
samples and identification of those patients at  risk of 
developing CMV disease after use of the limiting- 
dilution PCR. 
Monitoring the effect of antiviral therapy, using the 
limiting-dilution P C R  or the hybrid capture assay, 
showed a fall to undetectable levels of CMV DNA in 
approximately one-third of treatment courses. In 
another third of the courses, there was a decline in the 
load of CMV DNA. With the use of different methods, 
a decrease in CMV DNA load has been observed in 
patients who responded to antiviral therapy and allowed 
an assessment of the efficacy of the treatment [ l  1- 
16,45,36]. This is in line with our findings with the 
limiting-dilution P C R  or the hybrid capture assay. 
Persistent CMV PCR positivity a t  the end of antiviral 
therapy has also been observed. This has been 
associated with a risk of recurrent CMV disease 
[8,9,15,16,19]. Persistent CMV DNA in these patients 
may reflect a high initial amount of virus, an 
insufficient concentration of drug, or the development 
of ganciclovir-resistant strains of virus [37]. Therefore, 
it is important to identify the few patients who remain 
CMV DNA positive after antiviral treatment due to 
drug failure from the bulk of patients who remain 
positive due ro a high load initially but who show an 
appropriate decrease after treatment. 
Although there are various methods for defining 
CMV DNA or mRNA load. such as CMV DNA 
dilution factor, copy number, picogram, and the use of 
other blood components, there is a surprisingly similar 
outcome in the kinetics of CMV DNA load, during 
disease development and in relation to antiviral treat- 
ment. This study compared two methods of quanti- 
fication with each other and with virus isolation, which 
an international CMV workshop has decided should be 
the marker of CMV viremia 1261. Both methods 
identified patients a t  risk of developing CMV disease 
and allowed adequate monitoring of drug treatment. 
The limiting-dilution PCR was also useful for esti- 
mating the severity of CMV disease. 
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